Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gynecologic 27Breast 6Plasma cell 4Lymphoid 3Gastrointestinal 3Thoracic 2Other solid neoplasm 2Genitourinary 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Lymphoma 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Follicular 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × 1-dodecylpyridoxal × Lymphoid × Clear all
NCT06425302 2026-01-08

GOLSEEK-2

Celgene

Phase 2 Active not recruiting
90 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00785798 2022-04-04

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Yale University

Phase 1/2 Terminated
17 enrolled 4 charts
Lymphoid

Lymphoma

NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peking University

Phase 3 Unknown
244 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡